Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer

Histopathology

Volumn 65, Issue 5, 2014, Pages 684-692

  Preusser, Matthias ^a   Streubel, Berthold ^a,b   Berghoff, Anna S ^a   Hainfellner, Johannes A ^a,c   von Deimling, Andreas ^d,e   Widhalm, Georg ^a   Dieckmann, Karin ^a   Wöhrer, Adelheid ^a,c   Hackl, Monika ^f   Zielinski, Christoph ^a   Birner, Peter ^a,d,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f Austrian National Cancer Registry   (Austria)

Author keywords

CMET; Brain metastases; Fluorescence in situ hybridization; Immunohistochemistry; Lung cancer; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; SCATTER FACTOR RECEPTOR;

ADENOSQUAMOUS CARCINOMA; ARTICLE; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; CMET GENE; FEMALE; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA; ADULT; AGED; BRAIN; BRAIN TUMOR; CARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY;

ADENOCARCINOMA; ADULT; AGED; BRAIN; BRAIN NEOPLASMS; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84911360981     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12475     Document Type: Article

References (30)

1. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J. Clin. Oncol. 2013; 31; 1089-1096.
2. Landi L, Minuti G, D'Incecco A, Cappuzzo F. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. Curr. Opin. Oncol. 2013; 25; 130-136.
3. Sun W, Song L, Ai T et al. Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer. J. Biomed. Res. 2013; 27; 220-230.
4. Moschetta M, Basile A, Ferrucci A et al. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. Clin. Cancer Res. 2013; 19; 4371-4382.
5. Venepalli NK, Goff L. Targeting the HGF-cMET axis in hepatocellular carcinoma. Int. J. Hepatol. 2013; 2013; 341636.
6. Raghav KP, Wang W, Liu S et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin. Cancer Res. 2012; 18; 2269-2277.
7. Blumenschein GR Jr, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J. Clin. Oncol. 2012; 30; 3287-3296.
8. Zagouri F, Bago-Horvath Z, Rossler F et al. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br. J. Cancer 2013; 108; 1100-1105.
9. Mesteri I, Schoppmann SF, Preusser M, Birner P. Overexpression of cMet is associated with STAT3 activation and diminished prognosis in esophageal adenocarcinoma, but not in squamous cell cancer. Eur. J. Cancer 2014; 50; 1354-1360.
10. Park S, Choi YL, Sung CO et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol. Histopathol. 2012; 27; 197-207.
11. Tsuta K, Kozu Y, Mimae T et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J. Thorac. Oncol. 2012; 7; 331-339.
12. Dziadziuszko R, Wynes MW, Singh S et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J. Thorac. Oncol. 2012; 7; 340-347.
13. Preusser M, Capper D, Ilhan-Mutlu A et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol. 2012; 123; 205-222.
14. Breindel JL, Haskins JW, Cowell EP et al. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res. 2013; 73; 5053-5065.
15. Benedettini E, Sholl LM, Peyton M et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am. J. Pathol. 2010; 177; 415-423.
16. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
17. Woehrer A. Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry. Clin. Neuropathol. 2013; 32; 269-285.
18. Wohrer A, Waldhor T, Heinzl H et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J. Neurooncol. 2009; 95; 401-411.
19. Preusser M, Berghoff AS, Ilhan-Mutlu A et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer 2013; 80; 278-283.
20. Preusser M, Berghoff AS, Berger W et al. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer 2014; 83; 83-89.
21. Berghoff AS, Magerle M, Ilhan-Mutlu A et al. Frequent overexpression of ErbB - receptor family members in brain metastases of non-small cell lung cancer patients. APMIS 2014; (in press).
22. Berghoff AS, Ilhan-Mutlu A, Woehrer A et al. Proliferation, hypoxia and angiogenesis associate with survival in patients with brain metastases of non-small cell lung cancer. Strahlenther. Onkol. 2014; 190; 676-685.
23. Sperduto PW, Kased N, Roberge D et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 2012; 30; 419-425.
24. Bender R, Lange S. Adjusting for multiple testing-when and how? J. Clin. Epidemiol. 2001; 54; 343-349.
25. Han CB, Ma JT, Li F et al. EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis. Cancer Lett. 2012; 314; 63-72.
26. Stutz E, Gautschi O, Fey MF et al. Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology. Future Oncol. 2014; 10; 211-217.
27. Capelletti M, Gelsomino F, Tiseo M. MET and ALK as targets for the treatment of NSCLC. Curr. Pharm. Des. 2013; 20; 3914-3932.
28. Kitajima Y, Ide T, Ohtsuka T, Miyazaki K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 2008; 99; 1341-1347.
29. Xu L, Nilsson MB, Saintigny P et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 2010; 29; 2616-2627.
30. Wallace GC 4th, Dixon-Mah YN, Vandergrift WA 3rd et al. Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma. Metab. Brain Dis. 2013; 28; 355-366.